EXPERT HUB
Expertise: Drug Discovery
#prevention #clinicaltrials #cohorts #drugdiscovery #riskfactors #neuroimaging #pharmacology #exercise #nutrition #pollution #nursing #psychiatry #immunology #lifestyle #psychology #cognition #healthyageing #livingwell #stroke #mentalhealth #wayfinding
Sophie is a Senior Lecturer at the University of Glasgow's Institute of Molecular, Cell and Systems Biology and a member of the Scottish Dementia Research Consortium Executive Committee.
Research within Sophie's laboratory is focussed on defining the therapeutic potential of G protein-coupled receptors (GPCR) in neurodegenerative diseases, such as Alzheimer’s disease.
Specifically, the lab aim to exploit this family of cell-surface receptors to modulate neuroinflammatory processes, and in doing so, offer an approach for modifying progression of disease.
​
Working with a network of academic and industrial partners Sophie's group employ an array of experimental approaches which span through novel pharmacology to (chemo)genetic and neurodegenerative disease mouse models.
​
Dr Sophie Bradley
Professor Frank Gunn-Moore
Frank is the Head of the School of Biology at the University of St Andrews. He is also Deputy Director of the Scottish Universities Life Sciences Alliance and has sat on many different funding agencies.
​
Frank studied Biological Sciences at the University of Edinburgh, and then a PhD in Biochemistry at the University of Cambridge. After performing postdoctoral research at the Universities of Bristol and Edinburgh, he started my own group in St Andrews, which studies the development and survival of mammalian neurons.
Frank's approach to achieve this has been one of combining all three science disciplines, publishing in biological, chemical and physics-based journals.
​
His group have made major discoveries in understanding the early stages of Alzheimer’s disease, pioneering new models and identified potential therapeutic targets. In addition, they have developed novel optical technology that allows the manipulation and imaging of cells.
​
Expertise
#drugrepurposing
#drugdiscovery
#causalinference
#drugsafety
Dr Danielle Newby
Danielle is an early career dementia researcher with an interdisciplinary background in epidemiology, machine learning, and pharmacology. Since April 2016, she has been working as a post-doctorate researcher in the informatics team of the Translational Neuroscience and Dementia Research Group at the University of Oxford. Danielle is currently the lead of the Prevention working group for the DEMON network, which is a network applying data science and artificial intelligence to dementia research.
​
Her main research interests are: drug repurposing for dementia prevention; understanding and characterizing risk factors for dementia; inference and machine learning for dementia.
Danielle’s main areas of research within the team involve the analysis of real-world data such as medical electronic health records using traditional statistical approaches and machine learning. Using a wide variety of existing datasets and methods to triangulate evidence to understand more about what causes dementia and what we can do to intervene. By understanding these relationships this will provide an evidence base to support public health intervention for dementia prevention.